Press release

  1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | From 9 Next page Last page Next page

Title Date
SEPPIC launches CELEBRITY™, its new technology of macroalgal cell culture.
SEPPIC, through its subsidiary BiotechMarine, marks a major breakthrough in the field of marine biotechnology with CELEBRITY™.

March 4, 2015
SEPPIC receives the RSPO Mass Balance certification for its Castres (France) site
SEPPIC was awarded the Mass Balance* supply chain certification for its main production site in Castres (France). This certification of compliance with the RSPO (Round Table on Sustainable Palm Oil) standard enables SEPPIC to provide its customers with environmentally responsible ingredients.

March 4, 2015
SEPPIC presents new data on GELTRAP™: a environmentally friendly emulsion
GELTRAP™ is an environmentally friendly technology fully in line with SEPPIC's sustainable development strategy.

January 13, 2015
SEPITONIC M3: a new clinical study confirms increased cutaneous oxygenation
SEPPIC conducted this new in vivo test on thirty volunteers, proving the effectiveness of SEPITONIC M3 after just two hours of treatment*, as it resulted in an almost 10% increase in the skin's partial pressure of oxygen(1).

January 12, 2015
SEPPIC Opens Doors of New Production Unit, 1st Sterile High-Volume Packaging Line for Vaccine Adjuvants and Injectables
Today SEPPIC, a leader in the global market for vaccine adjuvants, is launching operations at its new production unit for vaccine adjuvants and injectables in Castres, France. The ultramodern facility puts SEPPIC at the cutting edge of technology. It is now the only company producing large quantities of sterile pharmaceutical excipients¹ and packaging them in pouches with volumes as great as 200 L. SEPPIC will eventually be offering sizes up to 1,000 L.

October 30, 2014
  1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | From 9 Next page Last page Next page

Print Send to a friend Bookmark this page Network

Text size        T- T+